Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Inhalable extracellular vesicles as cell-free therapeutics for chronic respiratory disease

Zhang P., Luo T., Song Z., He H., Yang Y., Jiang J.

Narrative Review on Face & Skin, Systemic / IV, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Bioeng Biotechnol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42110318
PMCID
PMC13149481
DOI
10.3389/fbioe.2026.1811444

Abstract (original English)

Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF), impose a significant burden on global health. The current drugs can mostly only alleviate symptoms or delay the progression, but are not very effective in reversing the structural remodeling, and are accompanied by obvious systemic adverse reactions. Extracellular vesicles (EVs), as nanoscale membrane-bound particles released by cells, possess excellent biocompatibility, low immunogenicity, and certain tissue targeting properties. They can also partially replicate the paracrine effects of cell therapy, providing a novel drug delivery platform for precise treatment of chronic respiratory diseases, and are particularly well-suited for inhalation administration. This review first provides an overview of the molecular profiles of major classes of native EVs, including those derived from mesenchymal stromal cells, pulmonary tissues, and non-pulmonary sources such as serum or plasma, platelets, and milk, and summarizes their respective therapeutic potentials in chronic respiratory pathologies. Subsequently, the key points focus on summarizing the research progress in engineering EVs through strategies such as optimizing cultivation conditions, surface targeted modification, and loading of active substances, in order to adapt them for inhalation delivery.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research